NCT00882570View on ClinicalTrials.gov

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Healthy
Interventions
DRUG

Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)

DRUG

Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00882570 - To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions | Biotech Hunter | Biotech Hunter